Cantor Fitzgerald Reiterates a Buy Rating on TrovaGene

By Jason Carr

In a report released today, Bryan Brokmeier from Cantor Fitzgerald reiterated a Buy rating on TrovaGene (NASDAQ: TROV), with a price target of $8. The company’s shares opened today at $3.65.

Brokmeier said:

“In-line 3Q16 results. TROV reported 3Q16 total revenue of $0.09M, compared to our estimate of $0.17M and consensus of $0.30M. GAAP loss-per-share of ($0.34) was in line with our estimate, but $0.01 wider than consensus of $0.33.”

According to, Brokmeier is a 1-star analyst with an average return of -2.2% and a 42.2% success rate. Brokmeier covers the Healthcare sector, focusing on stocks such as Rosetta Genomics Ltd, Pacific Biosciences, and Laboratory Corp.

TrovaGene has an analyst consensus of Moderate Buy.

The company has a one year high of $7.18 and a one year low of $2.85. Currently, TrovaGene has an average volume of 219.5K.

Trovagene, Inc. is a molecular diagnostic company, which focuses on the development and commercialization of a proprietary urine-based molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. Its focus is to leverage its novel cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes developing collaborations in the areas of infectious disease, transplant medicine and prenatal diagnostics. The company’s proprietary urine-based molecular diagnostic tests are designed to detect specific nucleic acids in urine which are known as transrenal DNA and RNA. Its technology is applied in various testing, such as tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. Trovagene was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.